George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles

Cronos Group: Buy the Dip?

Wall Street has turned sour on Cronos' near-term outlook. Should everyday investors do the same?